D
Phathom Pharmaceuticals, Inc.
PHAT
$4.41
$0.194.50%
D
Sell
3/7/2025Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 3/7/2025 due to an increase in the growth index and volatility index. Total revenue increased 81.41% from $16.35M to $29.66M, earnings per share increased from -$1.3242 to -$1.0479, and EBIT increased 16.07% from -$70.8M to -$59.42M.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 3/7/2025 due to an increase in the growth index and volatility index. Total revenue increased 81.41% from $16.35M to $29.66M, earnings per share increased from -$1.3242 to -$1.0479, and EBIT increased 16.07% from -$70.8M to -$59.42M.
E
Sell
3/6/2025Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 3/6/2025 due to a decline in the total return index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 3/6/2025 due to a decline in the total return index and volatility index.
D
Sell
2/12/2025Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 2/12/2025 due to an increase in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 2/12/2025 due to an increase in the volatility index.
E
Sell
1/28/2025Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 1/28/2025 due to a decline in the volatility index and growth index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 1/28/2025 due to a decline in the volatility index and growth index.
D
Sell
7/15/2024Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 7/15/2024 due to an increase in the total return index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 7/15/2024 due to an increase in the total return index and volatility index.
E
Sell
6/28/2024Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 6/28/2024 due to a decline in the total return index, volatility index and valuation index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 6/28/2024 due to a decline in the total return index, volatility index and valuation index.
D
Sell
6/4/2024Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 6/4/2024 due to an increase in the volatility index and total return index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 6/4/2024 due to an increase in the volatility index and total return index.
E
Sell
5/17/2024Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index.
D
Sell
5/2/2024Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 5/2/2024 due to an increase in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 5/2/2024 due to an increase in the volatility index.
E
Sell
4/17/2024Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 4/17/2024 due to a decline in the volatility index.
D
Sell
4/1/2024Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 4/1/2024 due to an increase in the total return index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 4/1/2024 due to an increase in the total return index and volatility index.
E
Sell
3/14/2024Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 3/14/2024 due to a noticeable decline in the growth index and volatility index. EBIT declined 95.95% from -$35.66M to -$69.88M, earnings per share declined from -$0.7616 to -$1.3888, and operating cash flow declined 37.23% from -$31.91M to -$43.8M.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 3/14/2024 due to a noticeable decline in the growth index and volatility index. EBIT declined 95.95% from -$35.66M to -$69.88M, earnings per share declined from -$0.7616 to -$1.3888, and operating cash flow declined 37.23% from -$31.91M to -$43.8M.
D
Sell
3/1/2024Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 3/1/2024 due to an increase in the volatility index and total return index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 3/1/2024 due to an increase in the volatility index and total return index.
E
Sell
2/14/2024Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 2/14/2024 due to a decline in the total return index, volatility index and growth index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 2/14/2024 due to a decline in the total return index, volatility index and growth index.
D
Sell
1/25/2024Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index and valuation index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index and valuation index.
E
Sell
1/9/2024Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 1/9/2024 due to a decline in the total return index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 1/9/2024 due to a decline in the total return index and volatility index.
D
Sell
12/18/2023Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index.
E
Sell
12/1/2023Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 12/1/2023 due to a decline in the volatility index and total return index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 12/1/2023 due to a decline in the volatility index and total return index.
D
Sell
11/10/2023Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index and growth index. Earnings per share increased from -$0.8446 to -$0.7616.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index and growth index. Earnings per share increased from -$0.8446 to -$0.7616.
E
Sell
8/2/2023Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 8/2/2023 due to a decline in the total return index, volatility index and growth index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 8/2/2023 due to a decline in the total return index, volatility index and growth index.
D
Sell
7/13/2023Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 7/13/2023 due to a noticeable increase in the total return index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 7/13/2023 due to a noticeable increase in the total return index and volatility index.
E
Sell
6/27/2023Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 6/27/2023 due to a decline in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 6/27/2023 due to a decline in the volatility index.
D
Sell
6/6/2023Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 6/6/2023 due to an increase in the volatility index and total return index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 6/6/2023 due to an increase in the volatility index and total return index.
E
Sell
5/19/2023Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 5/19/2023 due to a decline in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 5/19/2023 due to a decline in the volatility index.
D
Sell
5/8/2023Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 5/8/2023 due to an increase in the volatility index and total return index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 5/8/2023 due to an increase in the volatility index and total return index.
E
Sell
4/21/2023Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index, total return index and valuation index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/31/2023Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 3/31/2023 due to an increase in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 3/31/2023 due to an increase in the volatility index.
E
Sell
3/16/2023Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 3/16/2023 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 16.22% from -$35.02M to -$40.7M, EBIT declined 9.67% from -$42.53M to -$46.64M, and earnings per share declined from -$1.3161 to -$1.3325.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 3/16/2023 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 16.22% from -$35.02M to -$40.7M, EBIT declined 9.67% from -$42.53M to -$46.64M, and earnings per share declined from -$1.3161 to -$1.3325.
D
Sell
2/23/2023Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 02/23/2023.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
1/4/2023Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 1/4/2023 due to a decline in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 1/4/2023 due to a decline in the volatility index.
D
Sell
12/13/2022Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 12/13/2022 due to an increase in the volatility index and total return index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 12/13/2022 due to an increase in the volatility index and total return index.
D
Sell
11/10/2022Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 11/10/2022 due to a large decline in the solvency index, growth index and volatility index. Debt to equity increased from -27.31 to -7.51, operating cash flow declined 36.16% from -$25.72M to -$35.02M, and the quick ratio declined from 9.84 to 8.6.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 11/10/2022 due to a large decline in the solvency index, growth index and volatility index. Debt to equity increased from -27.31 to -7.51, operating cash flow declined 36.16% from -$25.72M to -$35.02M, and the quick ratio declined from 9.84 to 8.6.
D
Sell
10/21/2022Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 10/21/2022 due to an increase in the total return index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 10/21/2022 due to an increase in the total return index and volatility index.
D
Sell
10/6/2022Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 10/6/2022 due to a decline in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 10/6/2022 due to a decline in the volatility index.
D
Sell
9/13/2022Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 9/13/2022 due to an increase in the valuation index, growth index and volatility index. Operating cash flow increased 42.98% from -$45.1M to -$25.72M.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 9/13/2022 due to an increase in the valuation index, growth index and volatility index. Operating cash flow increased 42.98% from -$45.1M to -$25.72M.
D
Sell
5/31/2022Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index and valuation index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index and valuation index.
E
Sell
5/13/2022Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 5/13/2022 due to a decline in the growth index, solvency index and total return index. Debt to equity increased from 1.25 to 2.41, EBIT declined 14.73% from -$33.04M to -$37.91M, and earnings per share declined from -$0.9488 to -$1.0691.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 5/13/2022 due to a decline in the growth index, solvency index and total return index. Debt to equity increased from 1.25 to 2.41, EBIT declined 14.73% from -$33.04M to -$37.91M, and earnings per share declined from -$0.9488 to -$1.0691.
D
Sell
5/5/2022Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
3/4/2022Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 3/4/2022 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.86 to 1.25, and operating cash flow declined 42.51% from -$29.07M to -$41.42M.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 3/4/2022 due to a decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.86 to 1.25, and operating cash flow declined 42.51% from -$29.07M to -$41.42M.
D
Sell
2/25/2022Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 2/25/2022 due to an increase in the volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 2/25/2022 due to an increase in the volatility index.
D
Sell
2/7/2022Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 2/7/2022 due to a decline in the volatility index and valuation index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 2/7/2022 due to a decline in the volatility index and valuation index.
D
Sell
1/21/2022Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 1/21/2022 due to an increase in the valuation index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from D- on 1/21/2022 due to an increase in the valuation index and volatility index.
D
Sell
1/3/2022Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 1/3/2022 due to a noticeable decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.36 to 0.86.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D- from D on 1/3/2022 due to a noticeable decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.36 to 0.86.
D
Sell
11/9/2021Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from E+ on 11/09/2021.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D on 11/8/2021 due to a large decline in the volatility index, growth index and total return index. EBIT declined 5.17% from -$33.58M to -$35.32M, and earnings per share declined from -$0.9599 to -$0.9977.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E+ from D on 11/8/2021 due to a large decline in the volatility index, growth index and total return index. EBIT declined 5.17% from -$33.58M to -$35.32M, and earnings per share declined from -$0.9599 to -$0.9977.
D
Sell
6/28/2021Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D from D+ on 6/28/2021 due to a decline in the total return index and volatility index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D from D+ on 6/28/2021 due to a decline in the total return index and volatility index.
D
Sell
5/14/2021Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D+ from D on 5/14/2021 due to a noticeable increase in the growth index. Earnings per share increased from -$1.5772 to -$0.9599, and EBIT increased 35.96% from -$52.44M to -$33.58M.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D+ from D on 5/14/2021 due to a noticeable increase in the growth index. Earnings per share increased from -$1.5772 to -$0.9599, and EBIT increased 35.96% from -$52.44M to -$33.58M.
D
Sell
3/16/2021Downgrade
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D from D+ on 3/16/2021 due to a decline in the volatility index and valuation index.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to D from D+ on 3/16/2021 due to a decline in the volatility index and valuation index.
D
Sell
2/3/2021Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D+ from D on 2/3/2021 due to a noticeable increase in the growth index and total return index.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D+ from D on 2/3/2021 due to a noticeable increase in the growth index and total return index.
D
Sell
3/20/2020Upgraded
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from E on 3/20/2020 due to a significant increase in the solvency index, total return index and growth index. The quick ratio increased from 0.36 to 65.04, and earnings per share increased from -$9.2972 to -$3.9457.
Phathom Pharmaceuticals, Inc. (PHAT) was upgraded to D from E on 3/20/2020 due to a significant increase in the solvency index, total return index and growth index. The quick ratio increased from 0.36 to 65.04, and earnings per share increased from -$9.2972 to -$3.9457.
E
Sell
1/22/2020None
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E from U on 01/22/2020.
Phathom Pharmaceuticals, Inc. (PHAT) was downgraded to E from U on 01/22/2020.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
